 |
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B
Wednesday, October 17, 2007
On 12 October 2007, Gilead announced that it had submitted marketing applications to the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) for VireadŽ (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B in adults. Viread is already approved in the US and European Union for the treatment of HIV as part of combination antiretroviral therapy.
Click here for more information.
|
|
|
